-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2011, the FDA approved the first tumor immune checkpoint inhibitor, ipilimumab, a CTLA-4 blockade inhibitor, for the treatment of melanoma
Therefore, it is particularly important to understand immune checkpoints, immune checkpoint inhibitors, detection molecular markers, detection methods and criteria
Therefore, it is particularly important to understand immune checkpoints, immune checkpoint inhibitors, detection molecular markers, detection methods and criteria
1.
1.
PD-L1 (programmed death ligand 1) is a ligand for programmed death receptor 1 and a ligand for PD-1 (programmed cell death 1, programmed death receptor 1)
PD-L1 (programmed death ligand 1) is a ligand for programmed death receptor 1 and a ligand for PD-1 (programmed cell death 1, programmed death receptor 1)
Cancer cells suppress T cells through PD-L1
Cancer cells suppress T cells through PD-L1
PD-1 belongs to a transmembrane protein on the cell membrane and is expressed on immune cells such as T cells and B cells as well as tumor cells.
PD-1 belongs to a transmembrane protein on the cell membrane and is expressed on immune cells such as T cells and B cells as well as tumor cells.
PD1 signaling pathway
PD1 signaling pathway
2.
2.
Immune checkpoint inhibitors can combine with PD-1 or PD-L1 to block the control of immune function by tumor cells, ensure the function of immune cells such as T cells, and regain the clearance effect of T cells on tumors
Immune checkpoint inhibitors can combine with PD-1 or PD-L1 to block the control of immune function by tumor cells, ensure the function of immune cells such as T cells, and regain the clearance effect of T cells on tumors.
3.
3.
PD-L1 immunohistochemical detection is a simple and effective method to predict the efficacy of PD-1 or PD-L1 .
PD-L1 immunohistochemical detection is a simple and effective method to predict the efficacy of PD-1 or PD-L1 .
It detects the expression of PD-L1 on the surface of tumor cells (TC) or immune cells (IC) , and then speculates Methods of efficacy of PD-L1 inhibitors
.
Predicting PD-1 or PD-L1 efficacy on tumor cells (TC) or immune cells (IC)
At present, there are five commonly used immunohistochemical detection antibodies for PD-L1: 22C3, 28-8, SP263, SP142 and 73-10, as well as E1L3N commonly used in the laboratory
.
.
22C3, 28-8, SP263, SP142 and 73-10, as well as E1L3N commonly used in the laboratory
.
Four PD-L1 detection antibodies
Four PD-L1 detection antibodies
Different antibodies need to be detected with different detection platforms.
The mainstream detection platforms are 4 antibody detection platforms of the two companies, namely the AutoStainer Link 48 platform for DAKO 22C3 and 28-8 detection, and the Ventana Benchmark Ultra platform for Ventana SP142 and SP263 detection
.
The mainstream detection platforms are 4 antibody detection platforms of the two companies, namely the AutoStainer Link 48 platform for DAKO 22C3 and 28-8 detection, and the Ventana Benchmark Ultra platform for Ventana SP142 and SP263 detection
.
Fourth, the determination of immunohistochemical test results
4.Judgment of immunohistochemical test results 4.
Judgment of immunohistochemical test results
In addition to tumor cells (TC) expressing PD-L1, tumor-infiltrating immune cells (IC) also express PD-L1, so whether the content of these immune cells should be considered when defining the positive rate of PD-L1, tumor cells (TC) ) On the surface of PD-L1 and on the surface of immune cells (IC), which one is more suitable as a criterion for predicting the effect of PDL1 inhibitors?
In addition to tumor cells (TC) expressing PD-L1, tumor-infiltrating immune cells (IC) also express PD-L1, so whether the content of these immune cells should be considered when defining the positive rate of PD-L1, tumor cells (TC) ) On the surface of PD-L1 and on the surface of immune cells (IC), which one is more suitable as a criterion for predicting the effect of PDL1 inhibitors?
Therefore, for the determination of the positive rate of PD-L1, different companies use different methods for testing, and the standards for each method are also different
.
The determination methods used for PD-L1 detection antibodies include TPS, CPS, and calculation of TC and IC respectively
.
The main difference between different interpretation methods is whether to count the number of positive immune cells in the tumor area
.
.
The determination methods used for PD-L1 detection antibodies include TPS, CPS, and calculation of TC and IC respectively
.
The main difference between different interpretation methods is whether to count the number of positive immune cells in the tumor area
.
The determination methods used for PD-L1 detection antibodies include TPS, CPS, and calculation of TC and IC respectively
.
TPS is concerned with the expression of PD-L1 on the surface of tumor cells (TC).
CPS is a tumor cell with positive comprehensive membrane staining, and the number of lymphocytes and macrophages directly related to tumor cells, relative to the proportion of tumor cells (at least 100).
Fraction (CPS is a numerical value, not a %)
.
CPS is a tumor cell with positive comprehensive membrane staining, and the number of lymphocytes and macrophages directly related to tumor cells, relative to the proportion of tumor cells (at least 100).
Fraction (CPS is a numerical value, not a %)
.
TPS is concerned with the expression of PD-L1 on the surface of tumor cells (TC).
CPS is a tumor cell with positive comprehensive membrane staining, and the number of lymphocytes and macrophages directly related to tumor cells, relative to the proportion of tumor cells (at least 100).
Fraction (CPS is a numerical value, not a %)
.
1.
TPS: Tumor Proportion Score
TPS: Tumor Proportion Score 1.
TPS: Tumor Proportion Score
TPS=(PD-L1 membrane staining positive tumor cells/total tumor cells)×100%
TPS=(PD-L1 membrane staining positive tumor cells/total tumor cells)×100% TPS=(PD-L1 membrane staining positive tumor cells/total tumor cells)×100%
2.
CPS: Combined Positive Score
CPS: Combined Positive Score 2.
CPS: Combined Positive Score
CPS=(PD-L1 membrane staining positive tumor cells + PD-L1 membrane staining positive tumor-associated immune cells (lymphocytes, macrophages))/total tumor cells x 100
CPS=(PD-L1 membrane staining positive tumor cells + PD-L1 membrane staining positive tumor-associated immune cells (lymphocytes, macrophages))/total number of tumor cells x 100 CPS=(PD-L1 membrane staining positive tumor cells + PD -L1 membrane staining positive tumor-associated immune cells (lymphocytes, macrophages))/total tumor cells x100
3.
TC: tumor cell positive rate
TC: tumor cell positive rate 3, TC: tumor cell positive rate
TC=(any intensity of PD-L1 membrane staining positive tumor cells/total tumor cells) x 100%
TC=(any intensity of PD-L1 membrane staining positive tumor cells/total tumor cells) x 100% TC=(any intensity PD-L1 membrane staining positive tumor cells/total tumor cells) x 100%
4.
IC: positive rate of tumor-related immune cells
IC: positive rate of tumor-related immune cells 4.
IC: positive rate of tumor-related immune cells
IC = (number of tumor-associated immune cells with positive PD-L1 membrane staining at any intensity/total number of tumor-associated immune cells) x 100%
IC=(Number of tumor-associated immune cells with positive PD-L1 membrane staining at any intensity/total tumor-associated immune cells) x 100% IC=(Number of tumor-associated immune cells with positive PD-L1 membrane staining at any intensity/total tumor-associated immune cells Number) x100% 5.PD-L1 criteria for approved immune checkpoint inhibitors 5.
PD-L1 criteria for approved immune checkpoint inhibitors Companion diagnostics for nivolumab , Dako 28-8 and Ventana SP142 are complementary diagnostics for nivolumab and atezolizumab, respectively
.
Ventana SP263 is approved by the European Union as a complementary diagnostic for three immunosuppressants
.
Diagnosis Dako 28-8 and Ventana SP142 are complementary diagnoses for nivolumab and atezolizumab, respectively
PD-L1 IHC 22C3 PharmDx (DAKO) immunohistochemistry has been approved by the U.
S.
Food and Drug Administration (FDA) as a companion diagnostic for KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) in the treatment of tumors such as non-small cell lung cancer
S.
Food and Drug Administration (FDA) as a companion diagnostic for KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) in the treatment of tumors such as non-small cell lung cancer PD-L1 IHC 22C3 PharmDx (DAKO) immunohistochemistry has been approved by the U.
S.
Food and Drug Administration (FDA) as a companion diagnostic for KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) in the management of tumors such as non-small cell lung cancer
PD-L1 IHC SP263 (Ventana) immunohistochemistry has been approved by the FDA for complementary diagnosis of the following tumor immunotherapy drugs
PD-L1 IHC SP263 (Ventana) immunohistochemistry has been approved by the FDA for the supplemental diagnosis of the following tumor immunotherapy drugs PD-L1 IHC SP263 (Ventana) immunohistochemistry has been approved by the FDA for the supplementary diagnosis of the following tumor immunotherapy drugs tumor immunity
PD-L1 IHC SP142 (Ventana) immunohistochemistry has been approved by the FDA and recommended as a companion diagnostic for the following tumor immunotherapy drugs
PD-L1 IHC SP142 (Ventana) immunohistochemistry has been approved by the FDA and recommended for use as a companion diagnostic for the following tumor immunotherapy drugs PD-L1 IHC SP142 (Ventana) immunohistochemistry has been approved by the FDA and recommended for the following tumor immunotherapy drugs companion diagnosis
leave a message here